Step counts may predict trouble during lung cancer therapy
NCT ID NCT04878952
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether monitoring daily step counts in people with stage III non-small cell lung cancer during chemoradiotherapy helps doctors provide better supportive care and reduce hospital stays or treatment delays. Only 3 participants were enrolled before the study was stopped early. The approach aimed to catch problems early by watching activity levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
3 people
The number who actually took part.
- Started
-
Aug 2021
- Finished
-
Aug 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Pathologically (histologically or cytologically) proven diagnosis of NSCLC * Planned initiation (within the 30 days after study registration) of fractionated (≥15 treatments) thoracic radiotherapy with concurrent chemotherapy. Expected treatment scenarios include: * Definitive treatment of stage III disease (most common) * Definitive treatment for locoregional recurrence of early stage disease * Definitive treatment of unresectable stage II disease * Preoperative treatment of stage III disease * Postoperative treatment after incomplete resection (uncommon) * Radical treatment for a patient with advanced/metastatic disease with the goal of achieving long-term thoracic disease control (e.g., oligometastatic disease where metastases are addressed with resection or stereotactic radiotherapy) * ECOG Performance Status 0-3 within 30 days prior to registration * Age ≥ 18 * Ambulates independently or with a cane (use of a walker not permitted) * Patients who already use wearable devices and/or smartphones that monitor physical activity are eligible for this trial. Patients must agree to wear the device provided by the study. * The patient or a legally authorized representative must provide study-specific informed consent prior to study entry. Exclusion Criteria: * Patients with a history of another cancer that is expected to affect the toxicity profile of thoracic chemoradiotherapy for NSCLC * Patients receiving concurrent treatment for another cancer that is expected to affect the toxicity profile of thoracic chemoradiotherapy * Patients receiving thoracic radiotherapy without concurrent chemotherapy are ineligible. Patients receiving concurrent chemotherapy and another form of systemic therapy (e.g., immunotherapy) are eligible. Patients receiving radiotherapy with concurrent immunotherapy or targeted therapy but without chemotherapy are ineligible
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
WellSpan Health - Chambersburg
Chambersburg, Pennsylvania, 17201, United States
-
WellSpan Health - Ephrata
Ephrata, Pennsylvania, 17522, United States
-
WellSpan Health - Gettysburg
Gettysburg, Pennsylvania, 17325, United States
-
WellSpan Health - Lebanon
Lebanon, Pennsylvania, 17042, United States
-
WellSpan Health - York
York, Pennsylvania, 17403, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Surgeons could freeze lung tumors from miles away using 5G robots
- Two-Drug combo targets stubborn KRAS lung cancer
- Smaller chest drain may speed recovery after lung cancer surgery
- Gut bacteria may hold clues to why some cancer treatments work better
- Breath-Tracking sensor aims to sharpen lung cancer scans
- Can PET scan signals predict who beats lung cancer with immunotherapy?